Strategies to address low drug solubility in discovery and development.
about
The Prodrug Approach: A Successful Tool for Improving Drug SolubilityPolymorph Impact on the Bioavailability and Stability of Poorly Soluble DrugsFundamental aspects of solid dispersion technology for poorly soluble drugsA review of methods for the calculation of solution free energies and the modelling of systems in solutionEvaluation of antimalarial activity and toxicity of a new primaquine prodrugHigh-Throughput Excipient Discovery Enables Oral Delivery of Poorly Soluble PharmaceuticalsSmall-Scale Assays for Studying Dissolution of Pharmaceutical Cocrystals for Oral Administration.Multifunctional polymeric micelles for delivery of drugs and siRNA.Towards nanomedicines of the future: Remote magneto-mechanical actuation of nanomedicines by alternating magnetic fields.Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylateIsoenergetic Polymorphism: The Puzzle of Tolazamide as a Case Study.A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transportPeripherally cross-linking the shell of core-shell polymer micelles decreases premature release of physically loaded combretastatin A4 in whole blood and increases its mean residence time and subsequent potency against primary murine breast tumors aIn vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate.Sustained release of hydrophobic drugs by the microfluidic assembly of multistage microgel/poly (lactic-co-glycolic acid) nanoparticle composites.Using chiral molecules as an approach to address low-druggability recognition sites.Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112.Combinatorial screening for specific drug solubilizers with switchable release profiles.Naturally occurring proteinaceous nanoparticles in Coptidis Rhizoma extract act as concentration-dependent carriers that facilitate berberine absorption.ELQ-300 prodrugs for enhanced delivery and single-dose cure of malaria.Predicting human intestinal absorption in the presence of bile salt with micellar liquid chromatography.Multi-small molecule conjugations as new targeted delivery carriers for tumor therapy.Acyclic Cucurbit[n]uril-Type Molecular Container Enables Systemic Delivery of Effective Doses of Albendazole for Treatment of SK-OV-3 Xenograft TumorsMechanistic Analysis of Cocrystal Dissolution as a Function of pH and Micellar SolubilizationThe use of small-molecule structures to complement protein-ligand crystal structures in drug discoveryLipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway.Utilizing food effects to overcome challenges in delivery of lipophilic bioactives: structural design of medical and functional foods.Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures.Approaches to erythrocyte-mediated drug delivery.Excipient foods: designing food matrices that improve the oral bioavailability of pharmaceuticals and nutraceuticals.Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations.Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery.Utilization of nanoemulsions to enhance bioactivity of pharmaceuticals, supplements, and nutraceuticals: Nanoemulsion delivery systems and nanoemulsion excipient systems.The role of the carrier in the formulation of pharmaceutical solid dispersions. Part II: amorphous carriers.Rational excipient selection for co-amorphous formulations.Oral bioavailability enhancement through supersaturation: an update and meta-analysis.Complexation of oxethazaine with 2-hydroxypropyl-β-cyclodextrin: increased drug solubility, decreased cytotoxicity and analgesia at inflamed tissues.Design and evaluation of injectable niclosamide nanocrystals prepared by wet media milling technique.Synthesis and biological evaluation of novel 3-alkylpyridine marine alkaloid analogs with promising anticancer activity.Approaches to developing fast release pellets via wet extrusion-spheronization.
P2860
Q26771271-AB7FE8D5-7F53-4958-A55F-BB209E4B8EA2Q26779030-7136205D-312E-41D8-9DA1-D022F6A8DB12Q26822873-766E4F49-4F68-4741-BC48-D4C99CFC865CQ28256639-810257F8-F487-44E2-8B46-83192C2FB375Q28542047-E7FACE53-5918-40DE-8AFA-FD12C30D4E76Q28820788-26EFA12E-F2CC-4153-B3D4-CEC35153ABB4Q30375810-C4CD847E-AD9F-481D-A043-E7F060ADAF23Q30438973-3BA650F5-B3E9-4A99-BB4B-66EFE3F65490Q30746490-D86AE41B-A88C-40A7-B6F0-621F983984B6Q30985734-0D62149C-8D9C-4D32-9908-4F8F0D1B58B1Q33361425-415D3D43-3C37-44C7-A613-5BFB57B90559Q34060125-5C730CE1-3059-4CD1-93C8-C62E30BAC0B8Q35085896-33BF7E9B-147B-4036-B57B-8ED880D88FA9Q35136316-CE8DE9CF-5067-49B1-85EF-868955921A3AQ35224930-5EFCD27A-F92D-409E-B87B-15F74BC078B2Q35253755-F172D689-37D4-4CFD-AFE8-FB33D78525B6Q35284235-BE295231-376E-4B8B-881F-2DE367464EB3Q35537690-DA0D83AE-17E1-4B0F-AAF7-13FC1DE285BFQ35907872-FE1A07CE-0871-4965-954C-E53CD34924ACQ35960668-A453126E-AAA4-4815-9EEE-1BFFDDD21F69Q35977576-28A77AFF-989B-4859-B7FE-6EA41D2FFA7FQ36036923-777BC0A7-FD0B-4471-8169-BB7C7D6C3C4BQ36665183-3C21E80D-D5B0-4DA4-80E1-43EC7431068EQ36666790-70E3136A-06F0-4066-8F50-9CD0FEBF1397Q37698627-4E5B7F0E-CE58-42E5-8A7B-FC66998AD838Q38119168-E4CBBC37-5491-4C75-A0EB-A06E91A63513Q38140095-670250BC-D8A1-4F4D-A327-3D04D5E27751Q38179459-28E2B567-8A2B-40EA-9C70-5354B2284812Q38189095-297E3FEB-1D95-4255-8847-6B0FBB6AB455Q38206716-8EF16A36-3253-4E0E-BFEC-6D3DDA4D00FAQ38470559-D4389142-5861-448E-A516-98391C0D337AQ38729314-63E0089C-4463-42C1-A406-8BBA9CDAA4F3Q38777505-DAA0C777-6BA0-45C5-ADB9-4C9286E66B9BQ38856754-244D4B3D-D020-4FD6-BF7F-6E7A9FF060ADQ38856865-BE04FA14-391A-4AA6-8E34-9335EE787DF0Q38917369-03DD72BC-7054-4996-ABE8-3206C5E20751Q38955512-76A4E7EA-EE94-46FD-864A-0C5E26B7D0D3Q38958062-4A3C26BE-2A96-4816-98ED-1B36A7A3681BQ38968938-F63BB64D-AAEF-42E4-BC72-BDAD5325B2ABQ39018642-95D038EC-3866-458E-BE2A-F830DF6E0466
P2860
Strategies to address low drug solubility in discovery and development.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Strategies to address low drug solubility in discovery and development.
@en
type
label
Strategies to address low drug solubility in discovery and development.
@en
prefLabel
Strategies to address low drug solubility in discovery and development.
@en
P2093
P356
P1476
Strategies to address low drug solubility in discovery and development
@en
P2093
Christopher J H Porter
Hywel D Williams
Ravi M Shanker
Susan A Charman
William N Charman
P304
P356
10.1124/PR.112.005660
P577
2013-01-01T00:00:00Z